{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:44:54Z","timestamp":1789454694948,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Association Sport et Collection"},{"name":"France intergroupe des Leucemies My\u00e9loides Chroniques"},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PRT-K 2015-052"],"award-info":[{"award-number":["PRT-K 2015-052"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007394","name":"Association Laurette Fugain","doi-asserted-by":"publisher","award":["ALF 2015_10"],"award-info":[{"award-number":["ALF 2015_10"]}],"id":[{"id":"10.13039\/100007394","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association pour la Recherche en Immunologie-Poitou-Charentes"},{"DOI":"10.13039\/501100009895","name":"Canc\u00e9rop\u00f4le Grand Sud-Ouest","doi-asserted-by":"crossref","award":["API-K 2017"],"award-info":[{"award-number":["API-K 2017"]}],"id":[{"id":"10.13039\/501100009895","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ligue contre le Cancer du Grand Ouest","award":["Comit\u00e9s d\u00e9partementaux de la Vienne, de la Charente, de la Charente Maritime et des Deux-S\u00e8vres"],"award-info":[{"award-number":["Comit\u00e9s d\u00e9partementaux de la Vienne, de la Charente, de la Charente Maritime et des Deux-S\u00e8vres"]}]},{"DOI":"10.13039\/501100009468","name":"Conseil R\u00e9gional Aquitaine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009468","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation BMS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04256-0","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:49Z","timestamp":1766125369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Emilie","family":"Cayssials","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Decroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Jacomet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Piccirilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tartarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Chomel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ragot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Gombert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Barbarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4256_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2023.2023035","volume":"58","author":"JJ Han","year":"2023","unstructured":"Han JJ (2023) Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. Blood Res 58:S58\u2013S65. https:\/\/doi.org\/10.5045\/br.2023.2023035","journal-title":"Blood Res"},{"key":"4256_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"4256_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","volume":"40","author":"A Kreutzman","year":"2012","unstructured":"Kreutzman A, Jaatinen T, Greco D et al (2012) Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol 40:906-913.e1. https:\/\/doi.org\/10.1016\/j.exphem.2012.07.007","journal-title":"Exp Hematol"},{"key":"4256_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","volume":"6","author":"H Ureshino","year":"2018","unstructured":"Ureshino H, Shindo T, Kojima H et al (2018) Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res 6:745\u2013754. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0462","journal-title":"Cancer Immunol Res"},{"key":"4256_CR5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C et al (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129:1166\u20131176. https:\/\/doi.org\/10.1182\/blood-2016-10-745992","journal-title":"Blood"},{"key":"4256_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck O, Blom S, Dufva O et al (2018) Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32:1643\u20131656. https:\/\/doi.org\/10.1038\/s41375-018-0175-0","journal-title":"Leukemia"},{"key":"4256_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-021-00572-7","volume":"11","author":"Y-C Chang","year":"2021","unstructured":"Chang Y-C, Chiang Y-H, Hsu K et al (2021) Activated na\u00efve \u03b3\u03b4 T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer J 11:182. https:\/\/doi.org\/10.1038\/s41408-021-00572-7","journal-title":"Blood Cancer J"},{"key":"4256_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/eji.201545539","volume":"45","author":"F Jacomet","year":"2015","unstructured":"Jacomet F, Cayssials E, Basbous S et al (2015) Evidence for eomesodermin-expressing innate-like CD8(+) KIR\/NKG2A(+) T cells in human adults and cord blood samples. Eur J Immunol 45:1926\u20131933. https:\/\/doi.org\/10.1002\/eji.201545539","journal-title":"Eur J Immunol"},{"key":"4256_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00316","volume":"8","author":"A Barbarin","year":"2017","unstructured":"Barbarin A, Cayssials E, Jacomet F et al (2017) Phenotype of NK-like CD8(+) T cells with innate features in humans and their relevance in cancer diseases. Front Immunol 8:316. https:\/\/doi.org\/10.3389\/fimmu.2017.00316","journal-title":"Front Immunol"},{"key":"4256_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00688","volume":"7","author":"F Jacomet","year":"2017","unstructured":"Jacomet F, Cayssials E, Barbarin A et al (2017) The hypothesis of the human iNKT\/innate CD8(+) T-cell axis applied to cancer: evidence for a deficiency in chronic myeloid leukemia. Front Immunol 7:688. https:\/\/doi.org\/10.3389\/fimmu.2016.00688","journal-title":"Front Immunol"},{"key":"4256_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.15858","volume":"186","author":"E Cayssials","year":"2019","unstructured":"Cayssials E, Jacomet F, Piccirilli N et al (2019) Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol 186:54\u201359. https:\/\/doi.org\/10.1111\/bjh.15858","journal-title":"Br J Haematol"},{"key":"4256_CR12","doi-asserted-by":"publisher","first-page":"1473139","DOI":"10.3389\/fimmu.2024.1473139","volume":"15","author":"A Decroos","year":"2024","unstructured":"Decroos A, Meddour S, Demoy M et al (2024) The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy. Front Immunol 15:1473139. https:\/\/doi.org\/10.3389\/fimmu.2024.1473139","journal-title":"Front Immunol"},{"key":"4256_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.18486","volume":"200","author":"L Roy","year":"2023","unstructured":"Roy L, Chomel J-C, Guilhot J et al (2023) Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (DASA-PegIFN study). Br J Haematol 200:175\u2013186. https:\/\/doi.org\/10.1111\/bjh.18486","journal-title":"Br J Haematol"},{"key":"4256_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152585","volume":"132","author":"J Huuhtanen","year":"2022","unstructured":"Huuhtanen J, Ilander M, Yadav B et al (2022) IFN-\u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Invest 132:e152585. https:\/\/doi.org\/10.1172\/JCI152585","journal-title":"J Clin Invest"},{"key":"4256_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"4256_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398\u20131405. https:\/\/doi.org\/10.1038\/leu.2009.46","journal-title":"Leukemia"},{"key":"4256_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24096","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C et al (2015) Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol 90:819\u2013824. https:\/\/doi.org\/10.1002\/ajh.24096","journal-title":"Am J Hematol"},{"key":"4256_CR18","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","volume":"14","author":"A Knight","year":"2012","unstructured":"Knight A, Mackinnon S, Lowdell MW (2012) Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14:1110\u20131118. https:\/\/doi.org\/10.3109\/14653249.2012.700766","journal-title":"Cytotherapy"},{"key":"4256_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","volume":"108","author":"P Harrington","year":"2023","unstructured":"Harrington P, Dillon R, Radia D et al (2023) Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. Haematologica 108:1555\u20131566. https:\/\/doi.org\/10.3324\/haematol.2022.282005","journal-title":"Haematologica"},{"key":"4256_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood.V126.23.134.134","volume":"126","author":"L Roy","year":"2015","unstructured":"Roy L, Chomel J-C, Guilhot J et al (2015) Combination of dasatinib and Peg-Interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC). Blood 126:134\u2013134. https:\/\/doi.org\/10.1182\/blood.V126.23.134.134","journal-title":"Blood"},{"key":"4256_CR21","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28925","volume":"3","author":"A Kreutzman","year":"2014","unstructured":"Kreutzman A, Ilander M, Porkka K et al (2014) Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 3:e28925. https:\/\/doi.org\/10.4161\/onci.28925","journal-title":"Oncoimmunology"},{"key":"4256_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/leu.2013.221","volume":"28","author":"KN Wu","year":"2014","unstructured":"Wu KN, Wang YJ, He Y et al (2014) Dasatinib promotes the potential of proliferation and antitumor responses of human \u03b3\u03b4T cells in a long-term induction ex vivo environment. Leukemia 28:206\u2013210. https:\/\/doi.org\/10.1038\/leu.2013.221","journal-title":"Leukemia"},{"key":"4256_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914\u2013924. https:\/\/doi.org\/10.1038\/leu.2012.348","journal-title":"Leukemia"},{"key":"4256_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60195-z","volume":"10","author":"A Barbarin","year":"2020","unstructured":"Barbarin A, Abdallah M, Lef\u00e8vre L et al (2020) Innate T-\u03b1\u03b2 lymphocytes as new immunological components of anti-tumoral \u201coff-target\u201d effects of the tyrosine kinase inhibitor dasatinib. Sci Rep 10:1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-60195-z","journal-title":"Sci Rep"},{"key":"4256_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","volume":"38","author":"J Huuhtanen","year":"2024","unstructured":"Huuhtanen J, Adnan-Awad S, Theodoropoulos J et al (2024) Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia 38:109\u2013125. https:\/\/doi.org\/10.1038\/s41375-023-02074-w","journal-title":"Leukemia"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04256-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:38Z","timestamp":1766170898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4256"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04256-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7590855\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Lydia Roy, Agn\u00e8s Guerci-Bresler, Martine Escoffre-Barbe, St\u00e9phane Giraudier, Aude Charbonnier, Viviane Dubruille, Fran\u00e7oise Huguet, Hyacinthe Johnson-Ansah, Pascal Lenain, Shanti Ame, Gabriel Etienne, Delphine Rea, Pascale Cony-Makhoul, St\u00e9phane Courby, Jean-Christophe Ianotto, Laurence Legros, Antoine Machet, Val\u00e9rie Coiteux, Eric Hermet, Francois-Xavier Mahon, Philippe Rousselot, Franck Nicolini, Emilie Cayssials, and Fran\u00e7ois Guilhot were DASA-PegIFN study investigators.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"DASA-PegIFN study investigators"}},{"value":"The present work is a sub-study of the DASA-PegIFN study (EudraCT Number 2012\u2013003389-42, ClinicalTrials.gov. NCT01872442) approved by the National Health regulatory authorities and ethical committee (Poitiers, France). This study is a prospective, nonrandomized phase 2 trial conducted in 22 centers in France.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the participating patients provided their written informed consent for the clinical study and ancillary biological studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"16"}}